Efficacy of Sofosbuvir For the Treatment of Hepatitis C Genotype3

Hafiz Muhammad Umair Ahmad; Farah  Kanwal; Muhammad  Usama

doi:10.29054/apmc/2018.162

Hafiz Muhammad Umair Ahmad Women Medical Officer BHU 260RB, Faisalabad
Farah Kanwal Women Medical Officer BHU 260RB, Faisalabad
Muhammad Usama Emergency Medical Officer Mayo Hospital, Lahore

DOI: https://doi.org/10.29054/apmc/2018.162

Keywords: HCV, Genotype 3, Sofosbuvir

Abstract

Hepatitis C virus (HCV) infection rate is rising in the underdeveloped world and genotype 3 is the 2^nd most common subtype to involve. Sofosbuvir has shown good results in the recent times. Objective: To determine the efficacy of sofosbuvir for the treatment of hepatitis c genotype 3. Study Design: This was a descriptive case series study Place of Study: Medical wards of Sheikh Zayed Hospital, Lahore. Period: From January 2016 to July 2016. Methodology: The cases of HCV infection of genotype 3 assessed by PCR were included. These cases then were treated with oral sofosbuvir in a dose of 400 mg daily along with RBV with age appropriate doses. The efficacy was labelled as yes when there was negative result on PCR done at completion of 3 months. Results: In the present study there were total 200 patients that had HCV PCR positive for genotype III, out of which 112 (56%) were males and 88 (44%) were females with mean age of 46.21±4.27 years. Efficacy of sofosbuvir was seen in 184 (92%) of the patients. This efficacy was better in those that had age 50 or less where it was seen in 118 (94.4%) of cases as compared to 66 (88%) with age more than this (p=0.07). The duration of HCV less than 1 year revealed success rate of 96.67% as compared to 90% with p value of 0.08. Conclusion: Sofosbuvir has shown a very high efficacy rate in cases with HCV infection due to genotype 3 and results were near significantly better in those that had age less than 50 years and infection for less than 1 year.